Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
QURE
#2145
uniQure N.V.
15.6
3
-9.76%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-9.76%
Changement Mensuel
-34.90%
Evolution sur 6 mois
-1.01%
Changement Annuel
+33.02%
Clôture Précédente
17.3
2
Open
15.6
3
Bid
Ask
Low
15.6
3
High
15.6
3
Volume
137
Marchés
Actions des Marchés US
Soins de Santé
QURE
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
44.99 M
46.46 M
46.98 M
47.84 M
54.08 M
—
Valuation ratios
Enterprise value
1.38 B
407.26 M
798.09 M
90.16 M
796.07 M
4.71 B
Price to earnings ratio
—
2.95
-8.06
-1.07
-3.59
-22.97
Price to sales ratio
—
1.85
9.59
20.85
31.68
304.34
Price to cash flow ratio
—
3.37
7.04
2.26
4.7
31.94
Price to book ratio
—
1.63
2.14
1.59
127.24
149.22
Enterprise value to EBITDA ratio
-8.26
1.64
-4.11
-0.28
54.59
-31.41
Profitability ratios
Return on assets %
0.37
0.41
0.18
0.37
0.43
0.05
Return on equity %
0.51
0.55
0.27
1.49
35.48
2.37
Return on invested capital %
-537.78
796.56
-212.61
-426.75
-377.81
-373.73
Gross margin %
92.27
95.23
98.82
99.59
95.33
352.35
Operating margin %
-334.34
59.28
-134.44
-1 785.46
-679.58
-5 600.29
EBITDA margin %
-445.82
47.52
-182.45
-2 064.32
53.77
-1 009.24
Net margin %
333.27
62.9
119.07
1 947.09
883.35
1 295.26
Liquidity ratios
Quick ratio
—
—
6.19
8.68
—
—
Current ratio
9.47
17.09
6.28
8.85
9.74
38.84
Inventory turnover
—
—
0.18
0.01
—
—
Asset turnover
0.1
0.91
0.14
0.02
0.04
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.1
0.12
0.15
0.12
0.09
0.32
Long term debt to total equity ratio
0.15
0.17
0.22
0.49
-7.6
-18.79
Per share metrics
Operating cash flow per share
—
6.15
-3.1
-3.06
-3.76
-2.94
EBIT per share
—
5.19
-4.33
-7.31
-0.13
-1.09
EBITDA per share
—
5.32
-4.16
-6.86
0.3
-0.93
Total debt per share
—
—
—
—
—
—
Cash per share
—
11.88
7.55
12.96
7.56
34.6
Net current asset value per share
—
13.41
10.2
13.67
8.02
36.53
Tangible book value per share
—
10.79
8.38
2.53
-2.06
-1.69
Working capital per share
—
12.63
8.58
12.13
7.2
32.47
Book value per share
—
12.72
10.19
4.36
-0.14
4.52
uniQure N.V
uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.
Nouvelles
uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know (NASDAQ:QURE)
uniQure : résultats sous surveillance avec l’AMT-130 en suspens
uniQure earnings in focus as AMT-130 regulatory path looms
Stifel commente les actions uniQure après les remarques du commissaire de la FDA
Stifel comments on uniQure shares after FDA commissioner remarks
Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug
Applied Materials, Broadcom among market cap stock movers on Thursday
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
UniQure stock tumbles on FDA comments about gene therapy trial
uniQure stock initiated at Peerperform by Wolfe Research
Les investisseurs d’uniQure font face à une date limite le 13 avril pour un recours collectif
uniQure investors face April 13 deadline for class action lawsuit